TScan Therapeutics
TCRX
27 hedge funds and large institutions have $83.5M invested in TScan Therapeutics in 2021 Q3 according to their latest regulatory filings, with 27 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
53.91% more ownership
Funds ownership: 0% → 53.91% (+54%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.9M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$13.2M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$11.9M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$11.6M |
| 5 |
DIC
Deer IX & Co
Larchmont,
New York
|
+$11.6M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $8K | +$9.27K | +1,000 | New |
|
27
Wells Fargo
San Francisco,
California
| – | +$380 | +41 | New |
|
TCRX Hedge Fund Activity: Q3 2021 in Review
27 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q3 2021, worth a combined $83.5M.
Buyers outnumbered sellers: 27 funds opened new TCRX positions and 0 closed out — a net gain of 27 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $13.9M.
- 27 institutional investors held TScan Therapeutics (TCRX) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $83.5M of TScan Therapeutics stock for Q3 2021.
- 27 funds opened new TScan Therapeutics positions in Q3 2021 and 0 closed out, a net change of +27 holders.
- The largest TScan Therapeutics buyer in Q3 2021 was BlackRock, an estimated $13.9M added.
Based on aggregated 13F filings for Q3 2021.